{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T07:20:46Z","timestamp":1792740046669,"version":"4.5.0"},"reference-count":167,"publisher":"American Society for Microbiology","issue":"1","license":[{"start":{"date-parts":[[2006,1,1]],"date-time":"2006-01-01T00:00:00Z","timestamp":1136073600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.asm.org\/non-commercial-tdm-license"}],"content-domain":{"domain":["journals.asm.org"],"crossmark-restriction":true},"short-container-title":["Clin Microbiol Rev"],"published-print":{"date-parts":[[2006,1]]},"abstract":"<jats:sec>\n                    <jats:title>SUMMARY<\/jats:title>\n                    <jats:p>Leishmaniasis is a complex disease, with visceral and cutaneous manifestations, and is caused by over 15 different species of the protozoan parasite genus Leishmania. There are significant differences in the sensitivity of these species both to the standard drugs, for example, pentavalent antimonials and miltefosine, and those on clinical trial, for example, paromomycin. Over 60% of patients with visceral leishmaniasis in Bihar State, India, do not respond to treatment with pentavalent antimonials. This is now considered to be due to acquired resistance. Although this class of drugs has been used for over 60 years for leishmaniasis treatment, it is only in the past 2 years that the mechanisms of action and resistance have been identified, related to drug metabolism, thiol metabolism, and drug efflux. With the introduction of new therapies, including miltefosine in 2002 and paromomycin in 2005-2006, it is essential that there be a strategy to prevent the emergence of resistance to new drugs; combination therapy, monitoring of therapy, and improved diagnostics could play an essential role in this strategy.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1128\/cmr.19.1.111-126.2006","type":"journal-article","created":{"date-parts":[[2006,1,17]],"date-time":"2006-01-17T17:41:01Z","timestamp":1137519661000},"page":"111-126","update-policy":"https:\/\/doi.org\/10.1128\/asmj-crossmark-policy-page","source":"Crossref","is-referenced-by-count":1323,"title":["Drug Resistance in Leishmaniasis"],"prefix":"10.1128","volume":"19","author":[{"given":"Simon L.","family":"Croft","sequence":"first","affiliation":[{"name":"Department of Infectious and Tropical Diseases, London School of Hygiene and Tropical Medicine, London WC1E 7HT, United Kingdom"},{"name":"Infectious Diseases Research Laboratory, Department of Medicine, Institute of Medical Sciences, Banaras Hindu University, Varanasi 221 005, India"},{"name":"Division of Biological Chemistry and Molecular Biology, Wellcome Trust Biocentre, School of Life Sciences, University of Dundee, Dundee DD1 5EH, Scotland, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shyam","family":"Sundar","sequence":"additional","affiliation":[{"name":"Department of Infectious and Tropical Diseases, London School of Hygiene and Tropical Medicine, London WC1E 7HT, United Kingdom"},{"name":"Infectious Diseases Research Laboratory, Department of Medicine, Institute of Medical Sciences, Banaras Hindu University, Varanasi 221 005, India"},{"name":"Division of Biological Chemistry and Molecular Biology, Wellcome Trust Biocentre, School of Life Sciences, University of Dundee, Dundee DD1 5EH, Scotland, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alan H.","family":"Fairlamb","sequence":"additional","affiliation":[{"name":"Department of Infectious and Tropical Diseases, London School of Hygiene and Tropical Medicine, London WC1E 7HT, United Kingdom"},{"name":"Infectious Diseases Research Laboratory, Department of Medicine, Institute of Medical Sciences, Banaras Hindu University, Varanasi 221 005, India"},{"name":"Division of Biological Chemistry and Molecular Biology, Wellcome Trust Biocentre, School of Life Sciences, University of Dundee, Dundee DD1 5EH, Scotland, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"235","reference":[{"key":"e_1_3_2_2_2","doi-asserted-by":"publisher","DOI":"10.26719\/2003.9.4.837"},{"key":"e_1_3_2_3_2","first-page":"563","volume":"70","year":"1979","unstructured":"Aikat, B. K., S. Sahaya, A. G. Pathania, P. K. Bhattacharya, N. Desai, L. S. Prasad, S. Mishra, and S. Jain. 1979. Clinical profile of cases of kala-azar in Bihar. Indian J. Med. Res.70:563-570.","journal-title":"Indian J. Med. Res."},{"key":"e_1_3_2_4_2","unstructured":"Al-Jaser M. H. 1995. Drug sensitivity of cutaneous leishmaniasis in Al-Kharj Saudi Arabia. Ph.D. thesis. University of London London England."},{"key":"e_1_3_2_5_2","doi-asserted-by":"publisher","DOI":"10.1023\/A:1016251023427"},{"key":"e_1_3_2_6_2","first-page":"711","year":"1989","unstructured":"Allen, S., and R. A. Neal. 1989. The in vitro susceptibility of macrophages infected with amastigotes of Leishmania spp. to pentavalent antimonial drugs and other compounds with special relevance to cutaneous isolates, p. 711-720. In D. T. Hart (ed.), Leishmaniasis. Plenum Press, New York, N.Y.","journal-title":"Leishmaniasis"},{"key":"e_1_3_2_7_2","doi-asserted-by":"publisher","DOI":"10.1086\/324161"},{"key":"e_1_3_2_8_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0166-6851(01)00285-7"},{"key":"e_1_3_2_9_2","first-page":"353","volume":"81","year":"2003","unstructured":"Asilian, A., T. Jalayer, M. Nilforooshzadeh, R. L. Ghassemi, R. Peto, S. Wayling, P. Olliaro, and F. Modabber. 2003. Treatment of cutaneous leishmaniasis with aminosidine (paromomycin) ointment: double-blind, randomized trial in the Islamic Republic of Iran. Bull. W. H. O.81:353-359.","journal-title":"Bull. W. H. O."},{"key":"e_1_3_2_10_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.22.3.380"},{"key":"e_1_3_2_11_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.46.12.3731-3738.2002"},{"key":"e_1_3_2_12_2","doi-asserted-by":"publisher","DOI":"10.1016\/0166-6851(88)90166-1"},{"key":"e_1_3_2_13_2","doi-asserted-by":"publisher","DOI":"10.1097\/00002030-199910010-00015"},{"key":"e_1_3_2_14_2","doi-asserted-by":"publisher","DOI":"10.4269\/ajtmh.1981.30.566"},{"key":"e_1_3_2_15_2","first-page":"25","volume":"76","year":"1998","unstructured":"Berman, J. D., R. Badaro, C. P. Thakur, K. M. Wasunna, K. Behbehani, R. Davidson, F. Kuzoe, L. Pang, K. Weerasuriya, and A. D. Bryceson. 1998. Efficacy and safety of liposomal amphotericin B (AmBisome) for visceral leishmaniasis in endemic developing countries. Bull. W. H. O.76:25-32.","journal-title":"Bull. W. H. O."},{"key":"e_1_3_2_16_2","doi-asserted-by":"publisher","DOI":"10.4269\/ajtmh.1982.31.459"},{"key":"e_1_3_2_17_2","doi-asserted-by":"publisher","DOI":"10.1016\/0006-2952(87)90689-7"},{"key":"e_1_3_2_18_2","doi-asserted-by":"publisher","DOI":"10.4269\/ajtmh.1983.32.753"},{"key":"e_1_3_2_19_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.27.6.916"},{"key":"e_1_3_2_20_2","doi-asserted-by":"publisher","DOI":"10.1126\/science.287.5457.1479"},{"key":"e_1_3_2_21_2","doi-asserted-by":"publisher","DOI":"10.4269\/ajtmh.2004.70.72"},{"key":"e_1_3_2_22_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1471-4922(03)00069-2"},{"key":"e_1_3_2_23_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.47.10.3073-3079.2003"},{"key":"e_1_3_2_24_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-3156.2001.00795.x"},{"key":"e_1_3_2_25_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.42.12.3245"},{"key":"e_1_3_2_26_2","first-page":"66","volume":"10","year":"1993","unstructured":"Burguera, J. L., M. Burguera, Y. Petit de Pena, A. Lugo, and N. Anez. 1993. Selective determination of antimony(III) and antimony(V) in serum and urine and of total antimony in skin biopsies of patients with cutaneous leishmaniasis treated with meglumine antimonate. J. Trace Elem. Med. Biol.10:66-70.","journal-title":"J. Trace Elem. Med. Biol."},{"key":"e_1_3_2_27_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0021-9258(18)55077-8"},{"key":"e_1_3_2_28_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.41.4.818"},{"key":"e_1_3_2_29_2","doi-asserted-by":"publisher","DOI":"10.1016\/0166-6851(94)00154-5"},{"key":"e_1_3_2_30_2","first-page":"83","year":"1984","unstructured":"Carson, P. E. 1984. 8-aminoquinolines, p. 83-121. In W. Peters and W. H. G. Richards (ed.), Antimalarial drugs II. Springer-Verlag, Berlin, Germany.","journal-title":"Antimalarial drugs II"},{"key":"e_1_3_2_31_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.47.5.1529-1535.2003"},{"key":"e_1_3_2_32_2","doi-asserted-by":"publisher","DOI":"10.1016\/0035-9203(85)90200-7"},{"key":"e_1_3_2_33_2","doi-asserted-by":"publisher","DOI":"10.1016\/0035-9203(90)90263-E"},{"key":"e_1_3_2_34_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0166-6851(03)00162-2"},{"key":"e_1_3_2_35_2","doi-asserted-by":"publisher","DOI":"10.1086\/381203"},{"key":"e_1_3_2_36_2","doi-asserted-by":"publisher","DOI":"10.1016\/0166-6851(90)90092-Z"},{"key":"e_1_3_2_37_2","first-page":"165","year":"2003","unstructured":"Croft, S. L., and R. Brun. 2003. In vitro and in vivo models for the identification and evaluation of drugs active against Trypanosoma and Leishmania, p. 165-175. In A. H. Fairlamb, R. Ridley, and H. Vial (ed.), Drugs against parasitic diseases: R&D methodologies and issues. [Online.] World Health Organization, Geneva, Switzerland. http:\/\/www.who.int\/tdr\/publication\/publications\/prd-drug.htm .","journal-title":"Drugs against parasitic diseases: R&D methodologies and issues"},{"key":"e_1_3_2_38_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.pt.2003.09.008"},{"key":"e_1_3_2_39_2","unstructured":"Croft S. L. and K. Seifert. 2005. Miltefosine: interactions with other anti-leishmanial drugs. Abstracts of the 3rd World Congress on Leishmaniosis 10-15 April 2005 Palermo Italy p. 57."},{"key":"e_1_3_2_40_2","doi-asserted-by":"publisher","DOI":"10.2174\/1381612023396258"},{"key":"e_1_3_2_41_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(02)08160-6"},{"key":"e_1_3_2_42_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1432-1033.1995.tb20583.x"},{"key":"e_1_3_2_43_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0169-4758(99)01609-9"},{"key":"e_1_3_2_44_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.326.7385.377"},{"key":"e_1_3_2_45_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0966-842X(97)01033-0"},{"key":"e_1_3_2_46_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0966-842X(00)01873-4"},{"key":"e_1_3_2_47_2","doi-asserted-by":"publisher","DOI":"10.1042\/BJ20040283"},{"key":"e_1_3_2_48_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0035-9203(01)90223-8"},{"key":"e_1_3_2_49_2","doi-asserted-by":"publisher","DOI":"10.1179\/000349803225002499"},{"key":"e_1_3_2_50_2","doi-asserted-by":"publisher","DOI":"10.1016\/0166-6851(94)90095-7"},{"key":"e_1_3_2_51_2","doi-asserted-by":"publisher","DOI":"10.4269\/ajtmh.2001.65.685"},{"key":"e_1_3_2_52_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/44.1.71"},{"key":"e_1_3_2_53_2","first-page":"2471","volume":"45","year":"1986","unstructured":"Docampo, R., and S. N. Moreno. 1986. Free radical metabolism of antiparasitic agents. Fed. Proc.45:2471-2476.","journal-title":"Fed. Proc."},{"key":"e_1_3_2_54_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.42.8.2141"},{"key":"e_1_3_2_55_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/49.suppl_1.7"},{"key":"e_1_3_2_56_2","doi-asserted-by":"publisher","DOI":"10.1016\/0190-9622(92)70175-F"},{"key":"e_1_3_2_57_2","doi-asserted-by":"publisher","DOI":"10.1016\/0035-9203(87)90011-3"},{"key":"e_1_3_2_58_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.43.2.278"},{"key":"e_1_3_2_59_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.41.5.1064"},{"key":"e_1_3_2_60_2","doi-asserted-by":"publisher","DOI":"10.1016\/0014-4894(66)90082-8"},{"key":"e_1_3_2_61_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0001-706X(01)00197-8"},{"key":"e_1_3_2_62_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.45.6.1872-1875.2001"},{"key":"e_1_3_2_63_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.41.4.827"},{"key":"e_1_3_2_64_2","doi-asserted-by":"publisher","DOI":"10.1023\/A:1022823605068"},{"key":"e_1_3_2_65_2","doi-asserted-by":"publisher","DOI":"10.4269\/ajtmh.1994.51.758"},{"key":"e_1_3_2_66_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.45.3.913-916.2001"},{"key":"e_1_3_2_67_2","first-page":"1033","year":"2003","unstructured":"Fries, D. S., and A. H. Fairlamb. 2003. Antiprotozoal agents, p. 1033-1087. In J. Abraham (ed.), Burger's medicinal chemistry and drug discovery: chemotherapeutic agents. John Wiley & Sons, New York, N.Y.","journal-title":"Burger's medicinal chemistry and drug discovery: chemotherapeutic agents"},{"key":"e_1_3_2_68_2","first-page":"538","volume":"3","year":"2002","unstructured":"Garnier, T., and S. L. Croft. 2002. Topical treatment for cutaneous leishmaniasis. Curr. Opin. Investig. Drugs3:538-544.","journal-title":"Curr. Opin. Investig. Drugs"},{"key":"e_1_3_2_69_2","doi-asserted-by":"publisher","DOI":"10.1128\/CMR.12.4.501"},{"key":"e_1_3_2_70_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.85.20.7602"},{"key":"e_1_3_2_71_2","doi-asserted-by":"publisher","DOI":"10.1042\/bj0370198"},{"key":"e_1_3_2_72_2","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M403959200"},{"key":"e_1_3_2_73_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0166-6851(03)00142-7"},{"key":"e_1_3_2_74_2","doi-asserted-by":"publisher","DOI":"10.3201\/eid0912.030178"},{"key":"e_1_3_2_75_2","doi-asserted-by":"publisher","DOI":"10.1080\/00034983.1992.11812717"},{"key":"e_1_3_2_76_2","doi-asserted-by":"publisher","DOI":"10.1016\/0014-4894(89)90173-2"},{"key":"e_1_3_2_77_2","doi-asserted-by":"publisher","DOI":"10.1093\/emboj\/16.11.3057"},{"key":"e_1_3_2_78_2","first-page":"494","year":"2002","unstructured":"Guerin, P. J., P. Olliaro, S. Sundar, M. Boelaert, S. L. Croft, P. Desjeux, M. K. Wasunna, and A. D. Bryceson. 2002. Visceral leishmaniasis: current status of control, diagnosis, and treatment, and a proposed research and development agenda. Lancet Infect. Dis.ii:494-501.","journal-title":"Lancet Infect. Dis."},{"key":"e_1_3_2_79_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2958.1999.01634.x"},{"key":"e_1_3_2_80_2","doi-asserted-by":"publisher","DOI":"10.1042\/bj2720281"},{"key":"e_1_3_2_81_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF00933004"},{"key":"e_1_3_2_82_2","first-page":"314","volume":"39","year":"1991","unstructured":"Jha, S. N., N. K. Singh, and T. K. Jha. 1991. Changing response to diamidine compounds in cases of kala-azar unresponsive to antimonial. J. Assoc. Physicians India39:314-316.","journal-title":"J. Assoc. Physicians India"},{"key":"e_1_3_2_83_2","doi-asserted-by":"publisher","DOI":"10.1016\/0035-9203(83)90058-5"},{"key":"e_1_3_2_84_2","first-page":"868","volume":"40","year":"1992","unstructured":"Jha, T. K., N. K. Singh, and S. N. Jha. 1992. Therapeutic use of sodium stibogluconate in kala-azar from some hyperendemic districts of N. Bihar, India. (Abstract) J. Assoc. Physicians India40:868.","journal-title":"J. Assoc. Physicians India"},{"key":"e_1_3_2_85_2","unstructured":"Am. J. Trop. Med. Hyg."},{"key":"e_1_3_2_86_2","doi-asserted-by":"publisher","DOI":"10.1146\/annurev.biochem.73.011303.073706"},{"key":"e_1_3_2_87_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1574-6968.1994.tb07140.x"},{"key":"e_1_3_2_88_2","doi-asserted-by":"publisher","DOI":"10.4269\/ajtmh.1978.27.751"},{"key":"e_1_3_2_89_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0304-4017(01)00399-5"},{"key":"e_1_3_2_90_2","doi-asserted-by":"publisher","DOI":"10.1097\/00002030-199906180-00009"},{"key":"e_1_3_2_91_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkg356"},{"key":"e_1_3_2_92_2","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M102351200"},{"key":"e_1_3_2_93_2","doi-asserted-by":"publisher","DOI":"10.1126\/science.283.5403.806"},{"key":"e_1_3_2_94_2","doi-asserted-by":"publisher","DOI":"10.1093\/genetics\/154.3.985"},{"key":"e_1_3_2_95_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0020-7519(02)00091-7"},{"key":"e_1_3_2_96_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0190-9622(98)70483-9"},{"key":"e_1_3_2_97_2","doi-asserted-by":"publisher","DOI":"10.1086\/314896"},{"key":"e_1_3_2_98_2","doi-asserted-by":"publisher","DOI":"10.1042\/bj2880977"},{"key":"e_1_3_2_99_2","doi-asserted-by":"publisher","DOI":"10.1179\/000349803225002615"},{"key":"e_1_3_2_100_2","doi-asserted-by":"publisher","DOI":"10.1080\/00034983.1994.11812832"},{"key":"e_1_3_2_101_2","doi-asserted-by":"publisher","DOI":"10.1051\/parasite\/1998052167"},{"key":"e_1_3_2_102_2","doi-asserted-by":"publisher","DOI":"10.1006\/excr.1997.3500"},{"key":"e_1_3_2_103_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF00931504"},{"key":"e_1_3_2_104_2","first-page":"111","volume":"118","year":"1991","unstructured":"Marr, J. J. 1991. Purine analogs as chemotherapeutic agents in leishmaniasis and American trypanosomiasis. J. Lab. Clin. Med.118:111-119.","journal-title":"J. Lab. Clin. Med."},{"key":"e_1_3_2_105_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.42.2.352"},{"key":"e_1_3_2_106_2","doi-asserted-by":"publisher","DOI":"10.1086\/515085"},{"key":"e_1_3_2_107_2","doi-asserted-by":"publisher","DOI":"10.1179\/000349803225002516"},{"key":"e_1_3_2_108_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.93.19.10383"},{"key":"e_1_3_2_109_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.37.7.1504"},{"key":"e_1_3_2_110_2","doi-asserted-by":"publisher","DOI":"10.1172\/JCI114009"},{"key":"e_1_3_2_111_2","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/165.3.528"},{"key":"e_1_3_2_112_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/35.5.577"},{"key":"e_1_3_2_113_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/14.5.463"},{"key":"e_1_3_2_114_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0021-9258(19)86518-3"},{"key":"e_1_3_2_115_2","doi-asserted-by":"publisher","DOI":"10.1016\/0923-2508(91)90089-S"},{"key":"e_1_3_2_116_2","doi-asserted-by":"publisher","DOI":"10.1002\/j.1460-2075.1991.tb08035.x"},{"key":"e_1_3_2_117_2","doi-asserted-by":"publisher","DOI":"10.1006\/bbrc.1996.1098"},{"key":"e_1_3_2_118_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.47.8.2397-2403.2003"},{"key":"e_1_3_2_119_2","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M308352200"},{"key":"e_1_3_2_120_2","doi-asserted-by":"publisher","DOI":"10.2174\/1389450023347588"},{"key":"e_1_3_2_121_2","first-page":"1","volume":"73","year":"1981","unstructured":"Peters, W. 1981. The treatment of kala-azar-new approaches to an old problem. Indian J. Med. Res.73(Suppl.):1-18.","journal-title":"Indian J. Med. Res."},{"key":"e_1_3_2_122_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.48.7.2409-2414.2004"},{"key":"e_1_3_2_123_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.40.12.2785"},{"key":"e_1_3_2_124_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-3156.2004.01251.x"},{"key":"e_1_3_2_125_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0035-9203(03)90167-2"},{"key":"e_1_3_2_126_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0166-6851(02)00280-3"},{"key":"e_1_3_2_127_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.37.9.1842"},{"key":"e_1_3_2_128_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbrc.2003.09.227"},{"key":"e_1_3_2_129_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0924-8579(03)00125-0"},{"key":"e_1_3_2_130_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.42.12.3097"},{"key":"e_1_3_2_131_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.45.7.2064-2069.2001"},{"key":"e_1_3_2_132_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.41.5.972"},{"key":"e_1_3_2_133_2","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M005423200"},{"key":"e_1_3_2_134_2","doi-asserted-by":"publisher","DOI":"10.1038\/clpt.1991.61"},{"key":"e_1_3_2_135_2","doi-asserted-by":"publisher","DOI":"10.1006\/expr.2001.4663"},{"key":"e_1_3_2_136_2","doi-asserted-by":"publisher","DOI":"10.1016\/1043-6618(89)90192-8"},{"key":"e_1_3_2_137_2","doi-asserted-by":"publisher","DOI":"10.1086\/377133"},{"key":"e_1_3_2_138_2","doi-asserted-by":"publisher","DOI":"10.1086\/383321"},{"key":"e_1_3_2_139_2","doi-asserted-by":"publisher","DOI":"10.4269\/ajtmh.2002.66.147"},{"key":"e_1_3_2_140_2","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M301975200"},{"key":"e_1_3_2_141_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1432-1327.2000.01605.x"},{"key":"e_1_3_2_142_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-3156.2001.00778.x"},{"key":"e_1_3_2_143_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa021556"},{"key":"e_1_3_2_144_2","doi-asserted-by":"publisher","DOI":"10.1086\/377542"},{"key":"e_1_3_2_145_2","doi-asserted-by":"publisher","DOI":"10.1086\/318121"},{"key":"e_1_3_2_146_2","first-page":"394","volume":"83","year":"2005","unstructured":"Sundar, S., and H. W. Murray. 2005. Availability of miltefosine for the treatment of kala-azar in India. Bull. W. H. O.83:394-395.","journal-title":"Bull. W. H. O."},{"key":"e_1_3_2_147_2","doi-asserted-by":"publisher","DOI":"10.4269\/ajtmh.2001.65.193"},{"key":"e_1_3_2_148_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.308.6924.307"},{"key":"e_1_3_2_149_2","doi-asserted-by":"publisher","DOI":"10.1016\/0035-9203(94)90106-6"},{"key":"e_1_3_2_150_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0035-9203(01)90160-9"},{"key":"e_1_3_2_151_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0035-9203(00)90131-7"},{"key":"e_1_3_2_152_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.296.6636.1557"},{"key":"e_1_3_2_153_2","first-page":"103","volume":"93","year":"1991","unstructured":"Thakur, C. P., M. Kumar, and A. K. Pandey. 1991. Evaluation of efficacy of longer durations of therapy of fresh cases of kala-azar with sodium stibogluconate. Indian J. Med. Res.93:103-110.","journal-title":"Indian J. Med. Res."},{"key":"e_1_3_2_154_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.288.6421.895"},{"key":"e_1_3_2_155_2","first-page":"561","volume":"92","year":"1998","unstructured":"Thakur, C. P., G. P. Sinha, A. K. Pandey, N. Kumar, P. Kumar, S. M. Hassan, S. Narain, and R. K. Roy. 1998. Do the diminishing efficacy and increasing toxicity of sodium stibogluconate in the treatment of visceral leishmaniasis in Bihar, India, justify its continued use as a first-line drug? An observational study of 80 cases. Ann. Trop. Med. Parasitol.92:561-569.","journal-title":"Ann. Trop. Med. Parasitol."},{"key":"e_1_3_2_156_2","doi-asserted-by":"publisher","DOI":"10.1016\/0006-2952(85)90122-4"},{"key":"e_1_3_2_157_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-3156.2000.00555.x"},{"key":"e_1_3_2_158_2","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M311039200"},{"key":"e_1_3_2_159_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(00)04232-X"},{"key":"e_1_3_2_160_2","doi-asserted-by":"crossref","unstructured":"Wasunna M. K. J. R. RAashid J. Mbui G. Kirigi D. Kinoti H. Lodenyo J. M. Felton A. J. Sabin and J. Horton. 2005. A phase II dose-rising study of sitamaquine for the treatment of visceral leishmaniasis in Kenya. Am. J. Trop. Med. Hyg. 73 : 871-876.","DOI":"10.4269\/ajtmh.2005.73.871"},{"key":"e_1_3_2_161_2","first-page":"545","volume":"270","year":"2002","unstructured":"White, N. J., and W. Pongtavornpinyo. 2002. The de novo selection of drug-resistant malaria parasites. Proc. R. Soc. Lond. B270:545-554.","journal-title":"Proc. R. Soc. Lond. B"},{"key":"e_1_3_2_162_2","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M405635200"},{"key":"e_1_3_2_163_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00775-003-0468-1"},{"key":"e_1_3_2_164_2","first-page":"266","volume":"2","year":"2003","unstructured":"Yan, S. C., I. L. K. Wang, L. M. C. Chow, and H. Z. Sun. 2003. Rapid reduction of pentavalent antimony by trypanothione: potential relevance to antimonial activation. Chem. Commun.2:266-287.","journal-title":"Chem. Commun."},{"key":"e_1_3_2_165_2","doi-asserted-by":"crossref","unstructured":"Yardley V. S. L. Croft S. De Donker J. C. Dujardin K. Siddhartha C. Miranda A. Llanos-Cuentas and F. Chappuis. 2005. The sensitivity of clinical isolates of Leishmania from Peru and Nepal to miltefosine. Am. J. Trop. Med. Hyg. 73 : 272-275.","DOI":"10.4269\/ajtmh.2005.73.272"},{"key":"e_1_3_2_166_2","first-page":"1446","volume":"3","year":"2002","unstructured":"Yeates, C. 2002. Sitamaquine (GlaxoSmithKline\/Walter Reed Army Institute). Curr. Opin. Investig. Drugs3:1446-1452.","journal-title":"Curr. Opin. Investig. Drugs"},{"key":"e_1_3_2_167_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.47.9.2717-2724.2003"},{"key":"e_1_3_2_168_2","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M404383200"}],"container-title":["Clinical Microbiology Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/CMR.19.1.111-126.2006","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/CMR.19.1.111-126.2006","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,23]],"date-time":"2022-02-23T05:46:52Z","timestamp":1645595212000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.asm.org\/doi\/10.1128\/CMR.19.1.111-126.2006"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,1]]},"references-count":167,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2006,1]]}},"alternative-id":["10.1128\/CMR.19.1.111-126.2006"],"URL":"https:\/\/doi.org\/10.1128\/cmr.19.1.111-126.2006","relation":{},"ISSN":["0893-8512","1098-6618"],"issn-type":[{"value":"0893-8512","type":"print"},{"value":"1098-6618","type":"electronic"}],"subject":[],"published":{"date-parts":[[2006,1]]},"assertion":[{"value":"2006-01-01","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}